Literature DB >> 21827484

Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes.

Thorsteinn Loftsson1, Marcus E Brewster.   

Abstract

OBJECTIVES: Cyclodextrins are useful solubilizing excipients that have gained currency in the formulator's armamentarium based on their ability to temporarily camouflage undesirable physicochemical properties. In this context cyclodextrins can increase oral bioavailability, stabilize compounds to chemical and enzymatic degradation and can affect permeability through biological membranes under certain circumstances. This latter property is examined herein as a function of the published literature as well as work completed in our laboratories. KEY
FINDINGS: Cyclodextrins can increase the uptake of drugs through biological barriers if the limiting barrier component is the unstirred water layer (UWL) that exists between the membrane and bulk water. This means that cyclodextrins are most useful when they interact with lipophiles in systems where such an UWL is present and contributes significantly to the barrier properties of the membrane. Furthermore, these principles are used to direct the optimal formulation of drugs in cyclodextrins. A second related critical success factor in the formulation of cyclodextrin-based drug product is an understanding of the kinetics and thermodynamics of complexation and the need to optimize the cyclodextrin amount and drug-to-cyclodextrin ratios. Drug formulations, especially those targeting compartments associated with limited dissolution (i.e. the eye, subcutaneous space, etc.), should be carefully designed such that the thermodynamic activity of the drug in the formulation is optimal meaning that there is sufficient cyclodextrin to solubilize the drug but not more than that. Increasing the cyclodextrin concentration decreases the formulation 'push' and may reduce the bioavailability of the system.
CONCLUSIONS: A mechanism-based understanding of cyclodextrin complexation is essential for the appropriate formulation of contemporary drug candidates.
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827484     DOI: 10.1111/j.2042-7158.2011.01279.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  27 in total

Review 1.  Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies.

Authors:  Ana Cláudia Santos; Diana Costa; Laura Ferreira; Catarina Guerra; Miguel Pereira-Silva; Irina Pereira; Diana Peixoto; Nuno R Ferreira; Francisco Veiga
Journal:  Drug Deliv Transl Res       Date:  2021-02       Impact factor: 4.617

2.  Molecular cloning, and optimized production and characterization of recombinant cyclodextrin glucanotransferase from Bacillus sp. T1.

Authors:  Zhenyang Liu; Guogan Wu; Huawei Wu
Journal:  3 Biotech       Date:  2022-02-05       Impact factor: 2.406

Review 3.  Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Adv Drug Deliv Rev       Date:  2013-05-11       Impact factor: 15.470

4.  Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison.

Authors:  Jos Bloemers; Kim van Rooij; Leo de Leede; Henderik W Frijlink; Hans P F Koppeschaar; Berend Olivier; Adriaan Tuiten
Journal:  Br J Clin Pharmacol       Date:  2016-03-07       Impact factor: 4.335

5.  Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes.

Authors:  Pedro P G Guimaraes; Mingchee Tan; Tuomas Tammela; Katherine Wu; Amanda Chung; Matthias Oberli; Karin Wang; Roman Spektor; Rachel S Riley; Celso T R Viana; Tyler Jacks; Robert Langer; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-02       Impact factor: 9.776

Review 6.  Principles of pharmacology in the eye.

Authors:  Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood
Journal:  Br J Pharmacol       Date:  2017-10-10       Impact factor: 8.739

7.  β-Cyclodextrin inclusion complex to improve physicochemical properties of pipemidic acid: characterization and bioactivity evaluation.

Authors:  Rosa Iacovino; Filomena Rapuano; Jolanda Valentina Caso; Agostino Russo; Margherita Lavorgna; Chiara Russo; Marina Isidori; Luigi Russo; Gaetano Malgieri; Carla Isernia
Journal:  Int J Mol Sci       Date:  2013-06-25       Impact factor: 5.923

8.  Evaluation of in vitro toxicity of peptide (N-acetyl-Leu-Gly-Leu-COOH)-substituted-β-cyclodextrin derivative, a novel drug carrier, in PC-12 cells.

Authors:  Hamid Reza Sadeghnia; Faezeh Vahdati Hassani; Hamid Sadeghian; Maryam Miandehi; Farzin Hadizadeh; Gholamreza Karimi
Journal:  Daru       Date:  2013-12-20       Impact factor: 3.117

9.  Hydrocortisone/cyclodextrin complex electrospun nanofibers for a fast-dissolving oral drug delivery system.

Authors:  Asli Celebioglu; Tamer Uyar
Journal:  RSC Med Chem       Date:  2020-01-08

10.  Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.

Authors:  Victor Mangas-Sanjuan; Jorge Gutiérrez-Nieto; Magdalena Echezarreta-López; Isabel González-Álvarez; Marta González-Álvarez; Vicente-Germán Casabó; Marival Bermejo; Mariana Landin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.